News headlines about Intrexon (NYSE:XON) have trended somewhat positive recently, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Intrexon earned a media sentiment score of 0.19 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.390192774828 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the news articles that may have impacted Accern’s scoring:
- Intrexon Corporation (XON) Expected to Post Quarterly Sales of $48.79 Million (americanbankingnews.com)
- Head to Head Analysis: Intrexon (XON) and Codexis (CDXS) (americanbankingnews.com)
- INTREXON CORP : Change in Directors or Principal Officers, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- Intrexon Corporation (XON) Receives Consensus Recommendation of “Hold” from Brokerages (americanbankingnews.com)
- Analysts Anticipate Intrexon Corporation (XON) Will Post Earnings of -$0.31 Per Share (americanbankingnews.com)
XON has been the subject of several recent research reports. Northland Securities reissued a “buy” rating and set a $27.00 target price on shares of Intrexon in a research report on Friday, October 6th. Griffin Securities reissued a “buy” rating and set a $55.00 target price on shares of Intrexon in a research report on Friday, October 6th. Stifel Nicolaus boosted their target price on shares of Intrexon from $39.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, November 10th. Bank of America decreased their target price on shares of Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. Finally, JMP Securities reissued an “outperform” rating and set a $42.00 target price on shares of Intrexon in a research report on Thursday, October 5th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $38.50.
WARNING: “Intrexon (XON) Earns News Impact Score of 0.19” was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this report on another domain, it was illegally copied and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be read at https://sportsperspectives.com/2017/12/07/intrexon-xon-earns-news-impact-score-of-0-19.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with MarketBeat.com's FREE daily email newsletter.